Involvement of phospholipases D1 and D2 in sphingosine 1-phosphate-induced ERK (extracellular-signal-regulated kinase) activation and interleukin-8 secretion in human bronchial epithelial cells by WANG, Lixin et al.
Biochem. J. (2002) 367, 751–760 (Printed in Great Britain) 751
Involvement of phospholipases D1 and D2 in sphingosine 1-phosphate-
induced ERK (extracellular-signal-regulated kinase) activation and
interleukin-8 secretion in human bronchial epithelial cells
Lixin WANG*, Rhett CUMMINGS*, Peter USATYUK*, Andrew MORRIS†, Kaikobad IRANI‡ and Viswanathan NATARAJAN*1
*Department of Medicine, Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, MD 21224, U.S.A., †Department of Cell and Developmental
Biology, University of North Carolina, Chapel Hill, NC 27599, U.S.A., and ‡Division of Cardiology, Johns Hopkins University, Baltimore, MD 21224, U.S.A.
Sphingosine 1-phosphate (S1P), a metabolite of sphingomyelin
degradation, stimulates interleukin-8 (IL-8) secretion in human
bronchial epithelial (Beas-2B) cells. The molecular mechanisms
regulating S1P-mediated IL-8 secretion are yet to be completely
defined. Here we provide evidence that activation of phospho-
lipases D1 and D2 (PLD1 and PLD2) by S1P regulates the
phosphorylation of extracellular-signal-regulated kinase (ERK)
and IL-8 secretion in Beas-2B cells. S1P, in a time- and
dose-dependent manner, enhanced the threonine}tyrosine phos-
phorylation of ERK. The inhibition of S1P-induced ERK
phosphorylation by pertussis toxin and PD 98059 indicated
coupling of S1P receptors to G
i
and the ERK signalling cascade
respectively. Treatment of Beas-2B cells with butan-1-ol, but not
butan-3-ol, abrogated the S1P-induced phosphorylation of
Raf-1 and ERK, suggesting that PLD is involved in this acti-
vation. The roles of PLD1 and PLD2 in ERK activation and IL-8
secretion activated by S1P were investigated by infecting cells
INTRODUCTION
Sphingosine 1-phosphate (S1P), a bioactive sphingolipid derived
from the metabolism of sphingomyelin, has been implicated as a
mediator of cellular functions such as proliferation, differen-
tiation, apoptosis, tumour cell invasion, cell migration and
angiogenesis [1]. S1P-mediated cellular responses are due to its
action as an extracellular mediator and as an intracellular second












}Edg-8 (Edg is defined as endothelial differentiation gene)]
that bind to S1P with high affinity have been identified and







to multiple effector systems
such as Rho, adenylate cyclase, protein kinase C (PKC), mitogen-
activated protein kinases (MAPKs), phospholipases, phospha-
tidylinositol 3-kinase (PI 3-kinase) and non-receptor tyrosine
kinases [4–7]. S1P also increases intracellular Ca#+ levels via
activation of phospholipase C- and inositol 1,4,5-trisphosphate-
dependent Ca#+ release from the endoplasmic reticulum [8].
Recently, S1P has been shown to exhibit pro-inflammatory
effects by regulating interleukin-6 (IL-6) secretion in smooth
muscle cells and osteoblasts, as well as IL-8 secretion in bronchial
epithelial and ovarian cancer cells [9–12]. However, the signalling
Abbreviations used: AP-1, activator protein-1 ; DMEM, Dulbecco’s modified Eagle’s medium; Edg, endothelial differentiation gene; ERK, extracellular-
signal-regulated kinase ; FBS, fetal bovine serum; IL-8, interleukin-8 ; MAPK, mitogen-activated protein kinase ; MEK, MAPK/ERK kinase ; MEM, minimal
essential medium; NF-κB, nuclear factor-κB; PA, phosphatidic acid ; PBt, phosphatidylbutanol ; PC, phosphatidylcholine ; p.f.u., plaque-forming units ;
PI 3-kinase, phosphatidylinositol 3-kinase ; PIP2, phosphatidylinositol 4,5-bisphosphate ; PKC, protein kinase C; PLD, phospholipase D; PTx, pertussis
toxin ; S1P, sphingosine 1-phosphate ; the prefixes h and m denote human and mouse respectively.
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with adenoviral constructs of wild-type and catalytically inactive
mutants of PLD1 and PLD2. Infection of Beas-2B cells with the
wild-type constructs resulted in the activation of PLD1 and
PLD2 by S1P and PMA. Also, the enhanced production of
[$#P]phosphatidic acid and [$#P]phosphatidylbutanol in the pres-
ence of butan-1-ol and the increased phosphorylation of ERK by
S1P were blocked by the catalytically inactive mutants hPLD1-
K898R and mPLD2-K758R. Transient transfection of Beas-2B
cells with human PLD1 and mouse PLD2 cDNAs potentiated
S1P-mediated IL-8 secretion compared with vector controls. In
addition, PD 98059 attenuated IL-8 secretion induced by S1P
in a dose-dependent fashion. These results demonstrate that both
PLD1 and PLD2 participate in S1P stimulation of ERK phos-
phorylation and IL-8 secretion in bronchial epithelial cells.
Key words: adenoviral infection, ERK1}2, PLD isoenzymes,
Raf-1 activation, S1P receptors.
mechanisms responsible for induction of IL-6 or IL-8 secretion
by S1P have not been fully identified.
Phospholipase D (PLD) catalyses the hydrolysis of phospha-
tidylcholine (PC) andothermembrane phospholipids to phospha-
tidic acid (PA) and choline [13]. Two isoforms of PLD, PLD1
and PLD2, have been cloned and are being characterized for
regulation and cellular function [14,15]. PA mediates the bio-
logical and physiological functions of PLD either directly or
indirectly by its metabolism to lyso-PA or diacylglycerol. PA, a
second messenger in mammalian cells, regulates protein tyrosine
phosphatases, phosphatidylinositol 4-kinase, type Iα
phosphatidylinositol 4-phosphate 5-kinase, PI 3-kinase and
NADPH oxidase [16–20]. Furthermore, PA generated by the
PLD pathway binds to Raf-1, regulating its recruitment to the
membrane and subsequent participation in the MAPK signalling
cascade and signal transduction [21–23].
S1P activates PLD in several mammalian cell systems, in-
cluding airway}alveolar epithelial-derived cell lines such as
CFNPE9o− and A549 [24,25]. We recently demonstrated that
S1P is a potent activator of PLD and enhances IL-8 secretion in
the bronchial epithelial Beas-2B cell line [11]. In Beas-2B cells,
PLD activation and IL-8 secretion were sensitive to pertussis
toxin (PTx), indicating the coupling of S1P receptor signalling to
the heterotrimeric G-protein G
i
. Additionally, butan-1-ol, but
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not butan-3-ol, attenuated S1P-mediated IL-8 production,
suggesting the involvement of PLD-generated PA in IL-8 sec-
retion [11]. However, the mechanism(s) of S1P signal trans-
duction and the role of PLD in mediating IL-8 secretion in
airway epithelial cells are not well defined. In the present study,
we have characterized PLD isoenzyme (PLD1 and}or PLD2)
activation by S1P and examined the roles of PLD1 and}or PLD2
in the S1P-induced activation of extracellular-signal-regulated
kinase (ERK) and IL-8 secretion by transient infection of Beas-
2B cells with adenoviral constructs of wild-type and catalytically
inactive mutants of human (h)PLD1 and mouse (m)PLD2. We
show here that S1P activated both PLD1 and PLD2 in Beas-2B
cells, and overexpression of wild-type hPLD1 and mPLD2
enhanced ERK phosphorylation, while the catalytically inactive
mutants attenuated ERK phosphorylation by S1P. Furthermore,
S1P-induced IL-8 secretion was augmented in hPLD1- and
mPLD2-overexpressing cells. Evidence is also provided for a role
for PA generated by the PLD pathway in the phosphorylation of
Raf-1. These data show that activation of PLD1 and PLD2 is
involved in S1P-induced ERK phosphorylation and IL-8 se-
cretion in human bronchial epithelial cells.
MATERIALS AND METHODS
Materials
S1P was obtained from BIOMOL Research Labs (Plymouth,
PA, U.S.A.). PMA, fetal bovine serum (FBS), BSA (fraction V),
opti-MEM1 medium, butan-1-ol, butan-3-ol, phosphate-free
Dulbecco’s modified Eagle’s medium (DMEM), minimal essen-
tial medium (MEM) and DMSO were purchased from Sigma
Chemical Co. (St. Louis, MO, U.S.A.). PD 98059, phosphatidyl-
inositol 4,5-bisphosphate (PIP
#
) and PTx were obtained from
CalbiochemCorp. (La Jolla,CA,U.S.A.).Dioleoyl phosphatidyl-
butanol (PBt) and dioleoyl PC were purchased from Avanti
PolarLipids Corp. (Alabaster, GA,U.S.A.). [$H]Choline-labelled
PC and dioleoyl phosphatidylethanolamine were purchased from
America Radiolabeled Chemicals (St. Louis, MO, U.S.A.). [$#P]P
i
(carrier-free) was obtained from New England Nuclear (Boston,
MA, U.S.A.). Polyclonal antibodies against phospho-ERK were
purchased from Cell Signaling (Beverly, MA, U.S.A.). Antibody
for pan-ERK was obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, U.S.A.). Antibodies against Raf-1 and
phospho-specific Raf-1 (S338) were purchased from Upstate
Biotechnology (Lake Placid, NY, U.S.A.). Internal and N-
terminal antibodies for PLD1 and PLD2 and IL-8 ELISA kit
were purchased from Biosource International Inc. (Camarillo,
CA, U.S.A.). FuGENE 6 transfection reagent was obtained
from Roche (Indianapolis, IN, U.S.A.). Horseradish peroxidase-
conjugated secondary antibodies were procured from Bio-Rad
(Hercules, CA, U.S.A.). Enhanced chemiluminescence detection
reagents were obtained from Amersham Pharmacia Inc.
(Piscataway, NJ, U.S.A.). All other reagents were of analytical
grade and obtained commercially.
Cell culture
Human bronchial epithelial cells (Beas-2B; passage 32; kindly
provided by Dr Sherer Sanders, Division of Pulmonary and
Critical Care Medicine, Johns Hopkins University) were cultured
in MEM supplemented with 5% (v}v) FBS and antibiotics. Cells
were grown in T-75 cm# vented flasks at 37 °C in 5% CO
#
}95%
air to 90% confluence and subsequently propagated in 35 mm
dishes. Cells at 60–70% confluence were serum deprived by
incubation for 12–18 h in MEM containing 0.2% (v}v) FBS
prior to stimulation with S1P or other agents. All experiments
were carried out between passages 35 and 43.
Adenovirus production of wild-type and catalytically inactive PLD1
and PLD2
hPLD1b (wild type and K898R mutant) and mPLD2 (wild type
and K758R mutant) cDNAs from pCGN-hPLD1b and pCGN-
mPLD2 [15] were subcloned into the pshuttle-CMV vector.
Adenoviral DNA was produced by a double-recombination
event between co-transformed adenoviral backbone plasmid,
pAdEasy-1, and the shuttle vector carrying the PLD gene in
Escherichia coli strain BJ5183. The recombinant plasmid was
linearized and transfected into HEK293 cells to generate
replication-defective adenovirus. Generation of purified virus
[10"! plaque-forming units (p.f.u.)}ml] was carried out by the
University of Iowa Gene Transfer Vector Core.
Transfection and viral infection
To Beas-2B cells grown to C50% confluence in 35 mm dishes
was added purified adenovirus (50 p.f.u.}cell) in complete MEM
(volume 2 ml). After overnight culture, the virus-containing
medium was replaced with fresh complete medium for different
time periods, as indicated. For transient transfection, cells grown
in 12-well plates were transfected with hPLD1 and mPLD2
plasmids (0.5 µg of DNA}well) with FuGENE 6 (3 µl}well)
according to the manufacturer’s recommendations. Cells were
challenged with S1P or other agents 24–48 h after viral infection
or transfection with plasmids.
Measurement of PLD activation in intact cells
Beas-2B cells (80–90% confluence) were labelled with [$#P]P
i
(5 µCi}ml) in phosphate-free DMEM containing 0.2% (v}v)
FBS for 12–18 h at 37 °C in a 5% CO
#
}95% air incubator.
The radioactive medium was replaced with MEM, and cells were
challenged with S1P in MEM containing 0.1% BSA and 0.05%
butan-1-ol or butan-3-ol for specified time periods. Incubations
were terminated by the addition of 1 ml of methanol}HCl (100:
1, v}v) and lipids were extracted as described previously [26].
[$#P]PBt formed was quantified after separation of total radio-
active lipids by TLC with an upper phase of ethyl acetate}2,2,4-
trimethylpentane}acetic acid}water (65:10:15:50, by vol.) as the
developing solvent system. Unlabelled dioleoyl PBt was added as
a carrier during TLC separation, and radioactivity associated
with PBt was determined by liquid scintillation counting. All
values were normalized to 10' d.p.m. in total lipid extract, and
data are expressed as d.p.m.}dish.
Measurement of PLD1 and PLD2 activities in vitro
Briefly, Beas-2B cells infected with vector control, hPLD1 or
mPLD2 adenoviral constructs were scraped into 1 ml of lysis
buffer containing 25 mM Tris (pH 7.4), 1 mM EDTA and
protease inhibitors, and sonicated by a probe sonicator. A 30 µl
aliquot of cell lysate was mixed with 50 µl of lipid mix (5 µM PC,
88 µM phosphatidylethanolamine, 7 µM PIP
#
and
[$H]methylcholine-PC), 20 µl of 5¬assay buffer (250 mM Hepes,
pH 7.4, 5 mMEGTA, 400 mMKCl, 5 mMdithiothreitol, 15 mM
MgCl
#
and 10 mM CaCl
#
) plus 1 µg of activated ADP-
ribosylation factor. The mixture was incubated at 37 °C for
30 min. The reaction was stopped with 200 µl of 10% (v}v)
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trichloroacetic acid on ice and centrifuged, then the radioactivity
in the supernatant was counted and PLD activity was expressed
as pmol of [$H]PC hydrolysed per 30 min.
Measurement of IL-8 secretion
Beas-2B cells (C70% confluence) in 35 mm dishes were pre-
treated with specified agents for the indicated time periods, then
media were aspirated and cells were challenged with MEM alone
or MEM containing 0.1% BSA with or without S1P for 3 h.
After this time the supernatant was carefully removed, centri-
fuged at 5000 g for 5 min at 4 °C and stored at ®80 °C. The IL-
8 concentration in the medium was measured by ELISA.
Preparation of cell lysates and Western blot analysis
Beas-2B cells grown in 100 mm dishes (C70% confluence) were
stimulated with S1P, rinsed with ice-cold PBS and lysed in RIPA
buffer. Cell lysate was sonicated on ice and centrifuged at
10000 g for 5 min at 4 °C. Protein concentration was determined
with a BCA protein assay kit (Pierce Chemical Co., Rockford IL,
U.S.A.) using BSA as standard. The samples (10–20 µg of
protein) were subjected to SDS}PAGE, and proteins from the
gel were transferred to a PVDF membrane, blocked with 5%
(w}v) non-fat dry milk in TBST (25 mM Tris base, pH 7.4,
137 mM NaCl and 0.1% Tween 20) for 1 h and incubated with
primary antibodies against phospho-ERK, pan-ERK, PLD1
(internal plus N-terminal) or PLD2 (internal plus N-terminal) (1 :
1000 dilution) in TBST overnight at 4 °C. The membranes were
washed four times with TBST at 20 min intervals and then
incubated with either mouse or rabbit horseradish peroxidase-
conjugated secondary antibody (1:3000 dilution) for 2 h at room
temperature. The membranes were developed with an enhanced
chemiluminescence detection system according to the manu-
facturer’s instructions, and blots were quantified by densitometric
scanning and image analysis with Molecular Analyst software.
ERK phosphorylation was expressed as fold change normalized
to total ERK.
Assessment of Raf-1 phosphorylation
Beas-2B cells in 100 mm dishes were treated with medium alone
or medium containing S1P (1 µM) in the absence or presence of
butan-1-ol or butan-3-ol (0.05%) for 5 min. Cells were washed in
ice-cold PBS containing 1 mM sodium orthovanadate, scraped
into microcentrifuge tubes in RIPA buffer containing protease
and phosphatase inhibitors and lysed as described above. Cell
lysates, after boiling in SDS sample buffer, were resolved by
SDS}PAGE (equal amounts of protein were loaded), transferred
to a PVDF membrane and probed with phospho-specific anti-
Raf-1 antibody, and immunocomplexes were detected by
enhanced chemiluminescence.
Statistical analysis
All results were subjected to statistical analysis using one-way
ANOVA. Data are expressed as means³S.D. of triplicate
samples from at least three independent experiments.
RESULTS
S1P activates ERK1/2 in Beas-2B cells
Serum-deprived Beas-2B cells were challenged with S1P (1 µM)
and ERK activation was measured by Western blot analysis with
phospho-specific antibodies against tyrosine and threonine
residues. Total ERK was measured with pan-ERK antibodies.
As shown in Figure 1 (left panels), S1P stimulated ERK1}2
phosphorylation in a time-dependent manner. Enhanced
phosphorylation of ERK1}2 (C2-fold) was detected within
2 min of exposure to S1P, while maximum phosphorylation (C5-
fold) occurred at 15 min, and declined thereafter. However, even
at 60 min after S1P treatment, phosphorylation of ERK1}2 was
about 1.5-fold higher as compared with vehicle (Figure 1, left
panels). Immunoprecipitates of ERK from S1P (1 µM)-
challenged cells also exhibited enhanced phosphorylation of
myelin basic protein with [γ-$#P]ATP (results not shown), indi-
cating stimulation of the catalytic activity of ERK by S1P.
Furthermore, the S1P-induced phosphorylation of ERK was
dose-dependent. Phosphorylation of ERK1}2 was detected after
15 min of exposure to 100 nM S1P (2-fold increase over control),
which increased to C6-fold with 1 µM S1P (Figure 1, right
panels).
S1P-induced activation of ERK is sensitive to PTx and PD 98059
Previous studies have shown that, in many cell types, S1P






. We therefore investigated the effect of PTx on S1P-
mediated ERK1}2 activation. Beas-2B cells were pretreated with
PTx (50 ng}ml) for 12 h at 37 °C before challenging with S1P
(1 µM for 15 min). Figure 2 shows that PTx pretreatment almost
completely blocked S1P-induced ERK1}2 phosphorylation,
suggesting the involvement of G
i
-coupled S1P receptors in the
activation. Interestingly, PTx pretreatment also attenuated the
basal phosphorylation of ERK1}2 in Beas-2B cells.
To further examine the signalling pathways involved in the
activation of ERK, Beas-2B cells were pretreated with PD 98059,
a specific inhibitor of MAPK}ERK kinase (MEK). As shown in
Figure 3, PD 98059 at 10 µM suppressed both S1P- and PMA
(TPA)-induced phosphorylation of ERK1}2, by 80% and 95%
respectively. These results suggest that the S1P-induced activation
of ERK is coupled to G
i
and MEK signalling in Beas-2B cells.
Role of PLD in S1P-mediated ERK phosphorylation in Beas-2B
cells
PLD, in addition to its catalytic activity, also exhibits a trans-
phosphatidylation reaction. In the presence of short-chain pri-
mary (but not secondary or tertiary) alcohols, PLD catalyses the
accumulation of phosphatidylalcohol from PA by a trans-
phosphatidylation reaction. Thus the formation of phosphatidyl-
alcohol, which removes the PA from second messenger functions,
has been employed to imply a role for PLD in cell function.
Earlier studies have shown S1P stimulation of PLD in Beas-2B
cells [11]. To determine whether PLD activation by S1P regulates
ERK phosphorylation, serum-deprived Beas-2B cells were stimu-
lated with S1P (1 µM) for 15 min in the absence or presence of
butan-1-ol or butan-3-ol. As shown in Figure 4, butan-1-ol
(0.05%), but not butan-3-ol (0.05%), blocked S1P-induced
ERK1}2 phosphorylation without affecting the basal levels of
ERK, suggesting that PLD-generated PA is an upstream regu-
lator of S1P-induced ERK1}2 activation.
To further support the finding that S1P-induced PLD ac-
tivation is upstream of the ERK pathway, we examined the effect
of PD 98059 on S1P-mediated [$#P]PBt formation. As shown in
Figure 5, treatment with S1P (1 µM) or PMA (25 nM) for 15 min
stimulated PLD activity by C4- and 9-fold respectively over
basal levels. Pretreatment of cells with PD 98059 (25 µM for 1 h)
had no effect on either S1P- or PMA-induced [$#P]PBt generation
(Figure 5). However, pretreatment with PTx (100 ng}ml for 1 h)
effectively blocked (" 95%) S1P-induced, but not PMA-induced,
[$#P]PBt accumulation. These results strongly indicate that ERK
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Figure 1 S1P stimulates ERK phosphorylation in Beas-2B cells
Left panels : Beas-2B cells were challenged with S1P (1 µM) for various time periods as indicated, and cell lysates were analysed by Western blotting for phosphorylation of ERK and total ERK
with phospho-specific ERK and pan-ERK antibodies respectively. Right panels : Beas-2B cells were incubated with increasing concentrations of S1P as indicated for 15 min, and cell lysates were
analysed by Western blotting with phospho-specific and pan-ERK antibodies as described in the Materials and methods section. Values are means³S.D. from three independent experiments, and
fold increases in phosphorylation were normalized to total ERK.
Figure 2 PTx blocks S1P-induced ERK phosphorylation
Beas-2B cells (C70% confluence in 100 mm dishes) were serum deprived [MEM containing
0.2% (v/v) FBS] for 18 h prior to PTx (50 ng/ml) treatment for 12 h. Cells were challenged with
S1P (1 µM) for 15 min, then cell lysates were prepared as described in the Materials and
methods section, subjected to SDS/PAGE and Western blotted with phospho-specific and pan-
ERK antibodies. Values are means³S.D. of three independent experiments in triplicate. Fold
increases in ERK phosphorylation were normalized to total ERK.
is not involved in regulating S1P-mediated PLD activation in




Effect of PLD-generated PA on S1P-induced Raf-1
phosphorylation
As PA interacts directly with Raf-1, an essential component of
ERK signalling [27], we investigated the effect of PLD-generated
PA induced by S1P on the phosphorylation of Raf-1. Treatment
of Beas-2B cells with S1P (1 µM) for 5 min induced a 2-fold
increase in Raf-1 phosphorylation, as determined by Western
blotting with a phosphoserine-specific Raf antibody. However,
Figure 3 PD 98059 attenuates S1P- and PMA-mediated ERK
phosphorylation
Beas-2B cells (C70% confluence in 100 mm dishes) were serum deprived for 18 h prior to
treatment with PD 98059 for 60 min. Subsequently, cells were challenged with S1P (1 µM) or
PMA (TPA ; 25 nM) for 15 min in MEM with 0.1% BSA. Cell lysates were prepared as described
in the Materials and methods section, and subjected to SDS/PAGE and Western blotting with
phospho-specific ERK and pan-ERK antibodies. Shown is a representative gel. Values are
means³S.D. of triplicate determinations from three independent experiments.
in the presence of 0.05% butan-1-ol (but not butan-3-ol), S1P-
induced Raf-1 phosphorylation was significantly attenuated
(Figure 6). This supports the notion that the S1P-induced
generation of PA via PLD regulates the phosphorylation of Raf-
1 in human bronchial epithelial cells, which in turn regulates
downstream ERK1}2 activation.
Overexpression of hPLD1 and mPLD2 adenoviral constructs in
Beas-2B cells
To further examine the role of PLD isoenzymes (PLD1 and
PLD2) in S1P-mediated ERK phosphorylation and IL-8 sec-
retion, we generated adenoviral constructs of wild-type and
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Figure 4 Butan-1-ol, but not butan-3-ol, attenuates S1P-induced ERK
phosphorylation
Beas-2B cells (C70% confluence in 100 mm dishes) were serum deprived for 18 h in MEM
containing 0.2% (v/v) FBS. Cells were pretreated with MEM or MEM plus butan-1-ol or butan-
3-ol (0.05%) for 15 min and then challenged with S1P (1 µM) in 0.1% BSA for an additional
15 min. Cell lysates were subjected to SDS/PAGE and Western blotting with phospho-specific
and pan-ERK antibodies. Values are means³S.D. of triplicate determinations from three
independent experiments. Fold increases in ERK phosphorylation were normalized to total ERK
in the cell lysates. *P ! 0.05 compared with vehicle control ; **P ! 0.05 compared with S1P
treatment.
Figure 5 Effects of PD 98059 and PTx on S1P- and PMA-induced PLD
activation
Beas-2B cells (C80% confluence in 35 mm dishes) were labelled with [32P]Pi (5 µCi/ml) in
phosphate-free DMEM for 18 h, then radioactive medium was aspirated and cells were
pretreated with PD 98059 (25 µM) or PTx (100 ng/ml) for 1 h. Cells were challenged with
MEM or MEM containing either S1P (1 µM) or PMA (TPA ; 25 nM) in 0.1% BSA and 0.05%
butan-1-ol for 15 min. Lipids were extracted under acidic conditions and the [32P]PBt formed
was quantified after separation by TLC. Values are means³S.D. of three independent
experiments in triplicate, and are normalized to 106 d.p.m. in total lipids.
catalytically inactive mutants of hPLD1 and mPLD2. Beas-2B
cells were infected with the adenoviral constructs (50 p.f.u.}cell)
for 12, 24 and 48 h. Cell lysates were analysed for increased
expression of the PLD1 and PLD2 proteins, enhanced generation
of PA and PBt in response to agonists, and PLD1 and PLD2
activities in itro. As shown in Figure 7(A), infection of Beas-2B
cells with adenoviral constructs of wild-type hPLD1 and mPLD2
enhanced the expression of PLD1 and PLD2 proteins in a time-
dependent manner, with optimal expression observed at 48 h
after infection. Therefore this time point was chosen for all of the
overexpression studies. The functional significance of hPLD1
and mPLD2 overexpression was tested by determining the
accumulation of [$#P]PA and [$#P]PBt in the presence of butan-
1-ol via PLD activation. Overexpression of hPLD1 and mPLD2
wild types in Beas-2B cells increased the accumulation of [$#P]PA
under basal conditions and in response to S1P challenge com-
Figure 6 Effects of butan-1-ol and butan-3-ol on S1P-stimulated Raf-1
phosphorylation
Beas-2B cells were serum starved for 18 h, then stimulated with S1P (1 µM) for 5 min in the
presence of butan-1-ol or butan-3-ol (0.05%, v/v). Cell lysates were subjected to SDS/PAGE,
and Raf-1 phosphorylation was measured by Western blotting with a phosphoserine-specific
antibody. The extent of Raf-1 phosphorylation was normalized to total Raf-1. Values are
means³S.D. of triplicate determinations from three independent experiments. *P ! 0.05
compared with vehicle control ; **P ! 0.05 compared with S1P treatment ; ***P " 0.05
compared with S1P treatment (i.e. not significantly different).
pared with vector control cells (Figure 7B). In cells infected with
the wild-type constructs, PMA-induced PLD activation, as
determined by [$#P]PBt formation, was potentiated. Inhibition of
[$#P]PBt generation was observed in mutant infected cells com-
pared with vector controls (Figure 7C). In itro PLD1 and PLD2
activities, as measured by [$H]PC hydrolysis, were increased in
hPLD1- and mPLD2-overexpressing cells, while cells infected
with hPLD1 and mPLD2 mutants exhibited lower activity
(Figure 7D). These results demonstrate the overexpression of
PLD1 and PLD2 proteins by the adenoviral constructs and the
functional consequences of the overexpressed proteins in bron-
chial epithelial cells.
S1P activates both PLD1 and PLD2 in Beas-2B cells
As S1P stimulates PLD in human bronchial epithelial cells
[11,24], we investigated which of the isoenzymes of PLD are
activated by S1P in Beas-2B cells. In vector-infected cells, S1P
stimulated [$#P]PBt accumulation by 5-fold (vehicle,
581³27 d.p.m.; S1P, 3006³94 d.p.m.). Overexpression of
hPLD1 (vehicle, 1608³220 d.p.m.; S1P, 7760³439 d.p.m.) or
mPLD2 (vehicle, 6109³253 d.p.m.; S1P, 15737³217 d.p.m.)
enhanced both basal and S1P-induced [$#P]PBt accumulation
compared with vector controls. However, overexpression of the
catalytically inactive mutants of PLD1 (K898R; vehicle,
791³49 d.p.m.; S1P, 2257³140 d.p.m.) and mPLD2 (K758R;
vehicle, 786³186 d.p.m.; S1P, 1760³106 d.p.m.) partially
blocked S1P-mediated [$#P]PBt formation without altering basal
activity (Figure 8).
Overexpression of PLD1 and PLD2 enhances S1P-induced ERK
phosphorylation
To further establish a role for PLD1 and PLD2 in S1P-mediated
ERK phosphorylation, Beas-2B cells were infected with wild-
type and catalytically inactive mutants of hPLD1 and mPLD2
adenoviral constructs. Overexpression of wild-type hPLD1
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Figure 7 Overexpression of adenoviral constructs of wild-type and mutant hPLD1 and mPLD2 in Beas-2B cells
(A) Beas-2B cells (C50% confluence in 60 mm dishes) were infected with vector or with wild-type hPLD1 or mPLD2 adenoviral constructs (50 p.f.u./cell ; 3¬105 cells per dish) in complete
MEM for 12, 24 and 48 h. At the indicated time points, cell lysates were prepared as described in the Materials and methods section, and subjected to SDS/PAGE and Western blotting with
internal plus N-terminal PLD1 and PLD2 antibodies. (B) Beas-2B cells in 35 mm dishes were infected with vector or with wild-type or mutant hPLD1/mPLD2 adenoviral constructs (50 p.f.u./cell ;
1¬105 cells per dish) for 24 h. The cells were labelled with [32P]Pi (5 µCi/ml) in phosphate-free DMEM for 12–18 h, then radioactive medium was aspirated and cells were challenged with
MEM or MEM plus S1P (1 µM) in 0.1% BSA in the absence or presence of 0.05% butan-1-ol for 2 min. Lipids were extracted under acidic conditions and separated by TLC as described in
the Materials and methods section. Labelled phospholipids were visualized by autoradiography. (C) Beas-2B cells (C50% confluence in 35 mm dishes) were infected with vector or with wild-
type or mutant hPLD1/mPLD2 adenoviral constructs and labelled with [32P]Pi as indicated in (B). Cells were challenged with MEM or MEM plus PMA (TPA ; 25 nM) plus 0.05% butan-1-ol for
15 min. Lipids were extracted under acidic conditions and [32P]PBt formed was quantified after separation by TLC. Values are means³S.D. of three independent experiments in triplicate. (D)
Beas-2B cells (C70% confluence in 100 mm dishes) were infected with vector or with wild-type or mutant hPLD1/mPLD2 adenoviral constructs for 24 h. Cell lysates prepared in assay buffer,
as indicated in the Materials and methods section, were assayed for PLD1 and PLD2 activities in vitro in the presence of PIP2 and other cofactors, as described in the Materials and methods
section. PLD activity was expressed as pmol of [3H]choline released from [3H]PC/30 min. Values are means³S.D. of triplicate samples.
Figure 8 Effects of overexpression of wild-type and catalytically inactive mutants of hPLD1 and mPLD2 on S1P-induced [32P]PBt formation
Left panels : Beas-2B cells (C70% confluence in 35 mm dishes) were infected with wild-type or mutant hPLD1 (50 p.f.u./cell ; 2¬105 cells per dish) for 24 h and subsequently labelled with
[32P]Pi for 18 h as described in the Materials and methods section. Cells were rinsed in MEM and challenged with MEM or MEM plus S1P (1 µM) containing 0.1% BSA and 0.05% butan-1-
ol for 15 min. Lipids were extracted under acidic conditions and [32P]PBt formed was quantified after separation of the total labelled lipids by TLC. Values are means³S.D. of triplicate determinations
from three independent experiments, normalized to 106 d.p.m. in total lipid extracts. Right panels : Beas-2B cells in 60 mm dishes were infected with vector or with wild-type or mutant mPLD2,
labelled with [32P]Pi and challenged with S1P (1 µM) for 15 min as described above. [
32P]PBt formed was quantified after separation by TLC and data were normalized to 106 d.p.m. in total lipids.
Values are means³S.D. of three independent experiments in triplicate.
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Figure 9 Effects of overexpression of wild-type and mutant hPLD1 and mPLD2 on S1P-induced ERK phosphorylation
Left panels : Beas-2B cells (C70% confluence in 60 mm dishes) were infected with vector or with wild-type or mutant hPLD1 for 24 h. Cells were serum deprived for 3 h before challenging with
MEM or MEM plus S1P (1 µM) containing 0.1% BSA for 15 min. Right panels : Beas-2B cells were infected with vector or with wild-type or mutant mPLD2 as described above. Cell lysates were
subjected to SDS/PAGE and Western blotting with phospho-specific and pan-ERK antibodies. Values are means³S.D. of three independent experiments in triplicate. Fold increases in ERK
phosphorylation were normalized to total ERK in the cell lysates.
Figure 10 PD 98059 attenuates S1P-mediated IL-8 secretion
Beas-2B cells grown to C90% confluence in 60 mm dishes were serum deprived for 3 h. Cells
were pretreated with PD 98059, at the indicated concentrations, for 1 h prior to challenge with
MEM or MEM plus S1P (1 µM) containing 0.1% BSA for 15 min. The medium was carefully
removed, centrifuged at 5000 g for 5 min and the supernatant stored at ®80 °C for IL-8
measurement by ELISA. Values are means³S.D. of three independent experiments in triplicate.
*P ! 0.05 compared with S1P treatment alone.
(vehicle, 2.1³0.9-fold; S1P, 7.3³1.9-fold) and mPLD2 (vehicle
3.9³1.5-fold; S1P, 20.6³4.4-fold) increased both basal and
S1P-mediated phosphorylation ofERK1}2 comparedwith vector
control cells (vehicle, 1.0 ; S1P, 4.7³1.8-fold). Infecting the cells
with the catalytically inactive mutants of hPLD1 (vehicle,
0.9³0.1-fold; S1P, 1.8³0.6-fold) and mPLD2 (vehicle,
2.2³0.92-fold; S1P, 2.2³0.98-fold) abolished ERK1}2
phosphorylation mediated by S1P (Figure 9). These results
further confirm the involvement of both PLD1 and PLD2 in
ERK phosphorylation induced by S1P in Beas-2B cells.
Role of ERK in S1P-induced IL-8 secretion in Beas-2B cells
We have previously demonstrated that S1P-induced IL-8 sec-
retion is attenuated by butan-1-ol, but not by butan-3-ol, in
Beas-2B cells, suggesting regulation of IL-8 secretion by the PLD
signalling cascade [11]. As activation of PLD1 and PLD2 by S1P
also enhances ERK phosphorylation, it was important to exam-
ine the link between ERK phosphorylation and IL-8 secretion
mediated by PLD. As shown in Figure 10, S1P (1 µM) treatment
Figure 11 Overexpression of wild-type hPLD1 or mPLD2 potentiates S1P-
induced IL-8 secretion
Beas-2B cells grown to C50% confluence in 12-well plates were transiently transfected with
hPLD1 or mPLD2 cDNA (0.5 µg/well) using FuGENE 6 (3 µg/well), with Opti-MEM as the
transfection agent. After 5 h of exposure to the plasmids, the medium was replaced with 1 ml
of complete MEM/10% (v/v) FBS. After 48 h of transfection, cells were rinsed in MEM and
challenged with MEM or MEM plus S1P (1 µM) in 0.1% BSA for 3 h. The supernatants (1 ml)
were removed, centrifuged at 5000 g for 5 min and stored at ®80 °C for IL-8 determination
by ELISA. Values are means³S.D. of three independent experiments in triplicate. * and **
denote a significant difference (P ! 0.05) compared with S1P treatment of the vector control.
of Beas-2B cells for 3 h stimulated IL-8 secretion by 4-fold
compared with control cells exposed to MEM alone. Pre-
treatment of cells with PD 98059 (10 µM), a selective inhibitor of
MEK1}2 upstream of ERK, attenuated S1P-mediated IL-8
secretion (C40% of control).
To investigate the role of PLD1 and PLD2 in S1P-induced IL-
8 secretion, Beas-2B cells were infected with vector control or
wild-type adenoviral constructs prior to S1P stimulation.
Surprisingly, even in the vector control (LacZ), a high level of IL-
8 secretion was observed (results not shown). Therefore we
transiently overexpressed PLD1 and PLD2 in Beas-2B cells with
mammalian expression plasmids using FuGENE 6. As shown in
Figure 11, overexpression of PLD1 and PLD2 potentiated S1P-
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mediated IL-8 secretion compared with the vector control. These
data further establish a role for both PLD1 and PLD2 in S1P-
induced IL-8 secretion in bronchial epithelial cells.
DISCUSSION
S1P, a potent bioactive sphingolipid, has emerged as an important
extracellular and intracellular signalling molecule in mammalian
cells [1]. S1P mediates a number of cellular responses, including
cell proliferation, chemotaxis and angiogenesis [28–30]. Many
of the cellular responses to S1P are mediated by activation of
protein kinases, changes in intracellular Ca#+, stimulation
of phospholipaseCandPLDand transactivation of growth factor
receptors [1,3,31]. We have recently shown that S1P is also a
potent activator of IL-8 secretion in human bronchial epithelial
cells in culture, which was partially blocked by inhibitors of PKC
and Rho kinase [11]. Here we report that : (1) S1P activates both
PLD1 and PLD2 isoforms in Beas-2B cells ; (2) S1P-induced
phosphorylation of ERK is regulated by PLD1 and PLD2; and
(3) S1P-mediated IL-8 secretion is reliant on PLD1- and PLD2-
dependent ERK activation. The role of S1P and its receptors in
bronchial epithelial cell signal transduction has not been well
defined. In the present study, S1P-mediated PLD1 and PLD2
activation, ERK phosphorylation and IL-8 secretion are prob-
ably mediated by the S1P family of G-protein-coupled receptors.
S1P has been shown to activate PLD in a number of different
mammalian cell types [32–34]. However, most of these studies
did not identify the isoform(s) of PLD activated by S1P. As the
efficiency of transient transfection of bronchial epithelial cells
with FuGENE 6 or Lipofectamine is low (C5–10%), we devel-
oped adenoviral constructs of wild-type hPLD1 and mPLD2 and
the catalytically inactive K898R PLD1 and K758R mPLD2
mutants. Infection of Beas-2B cells with these adenoviral
constructs (50 p.f.u.}cell) for 12, 24 and 48 h produced " 90%
efficiency of infection, as determined by β-galactosidase staining
of vector-infected cells (results not shown) and enhanced protein
expression (Figure 7A). Using the adenoviral constructs, we
report here for the first time that S1P rapidly and transiently
activates both PLD1 and PLD2 in human bronchial epithelial
cells. Furthermore, the catalytically inactive mutants of hPLD1
and mPLD2 blocked the S1P-mediated activation of PLD1 and
PLD2 respectively. Interestingly, the inactive mutants of both
PLD1 and PLD2 showed inhibitory effects on endogenous PLD
activity (Figure 7D) and a downstream target such as ERK
phosphorylation. The mechanism(s) of inhibition by the inactive
mutants is unclear; however, this may occur through competition
for PLD binding to activators such as PIP
#
, ADP-ribosylation
factor and Rho. Recent studies in COS-7 cells suggest that PLD1
and PLD2 can exist as homodimers and heterodimers ; this may,
in part, explain the suppression of endogenous PLD activity by
the inactive mutants of PLD1 and PLD2 [35]. The signalling
pathways involved in S1P-mediated PLD1 and PLD2 stimulation
have not been characterized. In C2C12 skeletal muscle cells, S1P-
induced PLD activation was sensitive to PTx, low concentrations
of GF 109201X and rottlerin. These data suggest that, in C2C12
cells, activation of PLD by S1P is linked to a PTx-sensitive G-
protein-coupled S1P receptor, and the participation of both
PKCα and PKCδ in PLD stimulation [36]. In the present study,
S1P-induced PLD activation in Beas-2B cells also showed
sensitivity to PTx and inhibition by Y27632 and bisindolyl-
maleimide, suggesting the involvement of Rho kinase and PKC
[11]. Further studies with the adenoviral constructs of wild-type
and catalytically inactive mutants of PLD1 and PLD2 should
reveal the signalling pathways that are activated by S1P in
regulating PLD1 and PLD2 in human bronchial epithelial cells.
Enhancement of phosphorylation of ERK by S1P has been
shown in a variety of cell types [37–43]. In Beas-2B cells, PLD
activation and ERK phosphorylation in response to S1P were
inhibited by PTx, suggesting coupling of S1P receptor(s) to G
i
-
proteins. Also, PD 98059, an inhibitor of MEK1}2, attenuated
S1P-induced ERK phosphorylation, suggesting regulation of the
Ras}Raf}MEK}ERK signalling cascade in Beas-2B cells. Fur-
thermore, PD 98059 did not attenuated S1P- or PMA-induced
PLD activation, suggesting ERK stimulation downstream of
PLD in Beas-2B cells. A role for PKC, PI 3-kinase and Src has
been demonstrated in agonist-induced ERK activation [41] ;
however, in Beas-2B cells, inhibitors of PKC, PI 3-kinase or Src
had no effect on ERK phosphorylation induced by S1P (results
not shown). There have been several reports in the literature
demonstrating the participation of PLD in ERK phosphoryl-
ation. In NIH 3T3 cells, lyso-PA-stimulated ERK phos-
phorylation was increased on PLD1 overexpression [42]. In Rat
fibroblasts overexpressing the epidermal growth factor receptor,
epidermal growth factor-induced ERK activation was augmented
by increased PLD activity, whereas decreased PLD activity due
to dominant-negative PLD gene expression attenuated ERK
phosphorylation [43]. Also, insulin-stimulated ERK phosphoryl-
ation was decreased in HIRcB cells overexpressing PLD mutants
[23].
To elucidate the role of PLD in the S1P-induced
phosphorylation of ERK, we took advantage of the PLD-
catalysed transphosphatidylation of PA to phosphatidylalcohol,
in the presence of a short-chain primary alcohol, as an indication
of PLD}PA-dependent cellular responses. We found that, in
Beas-2B cells, butan-1-ol (but not butan-3-ol) blocked S1P-
induced ERK phosphorylation. Furthermore, neither butan-1-ol
nor butan-3-ol, at concentrations of 0.05%, increased basal
phosphorylation of ERK (Figure 4). The participation of PLD1
and PLD2 in ERK phosphorylation was also evident from the
adenoviral infection of Beas-2B cells with wild-type and cata-
lytically inactive (hPLD1-K898R and mPLD2-K789R) mutants.
In Beas-2B cells, overexpression of both hPLD1 and mPLD2
wild types increased [$#P]PBt formation by severalfold compared
with vector controls after stimulation with S1P (Figure 8). Also,
overexpression of PLD1 and PLD2 wild types enhanced basal
and S1P-mediated ERK phosphorylation, while the mutants
blocked the response to S1P (Figure 9). These results provide the
first direct evidence for PLD1 and PLD2 activation and in-
volvement inERKphosphorylationmediatedbyS1P in bronchial
epithelial cells. While PD 98059 blocked S1P-induced ERK
phosphorylation, it did not affect PLD activation (Figure 5),
suggesting that PLD activation is upstream of MEK and ERK
in Beas-2B cells. However, in vascular smooth muscle cells,
noradrenaline-induced PLD stimulation is dependent on ERK,
indicating involvement of the Ras}MEK}ERK pathway in
stimulation by PLD [44].
One of the critical components of the ERK activation cascade
is Raf-1. Recent studies indicate that an association between PA
and Raf is necessary, in some cell types, for recruitment of Raf-
1 to the membrane. However, PA does not activate Raf-1 in itro
or in io, suggesting participation of other signalling molecules
in the activation of the Raf-1 kinase [23]. Distinct binding
domains for PA and phosphatidylserine at the C-terminal domain
of Raf-1 have been identified [21]. A physiological role of PA
binding to Raf in the translocation of Raf to the plasma
membrane and subsequent activation of Raf-1 has been demon-
strated [23]. The present study did not address the binding or
translocation of Raf to the membrane in S1P-stimulated Beas-2B
cells. S1P enhanced the phosphorylation of Raf-1 at serine-338,
as determined by Western blotting with a phospho-specific
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antibody (Figure 6), and the addition of butan-1-ol (but not
butan-3-ol) attenuated the S1P-enhanced phosphorylation of
Raf-1. Earlier studies demonstrated that phosphorylation
of Raf-1 at serine-338}339, in addition to tyrosine-340}341, is an
essential regulatory event for the biological and enzymic activity
of Raf-1 [45–47]. Although it has been established that activated
Raf-1 phosphorylates MEK1, which in turn phosphorylates and
activates ERK1}2, it is unclear whether S1P-induced phosphoryl-
ation of Raf-1 at serine-338}339 regulates ERK. As PA generated
by PLD signalling recruits Raf-1 to the plasma membrane for
subsequent activation by Ras, our results also indicate a role
for PA in Raf-1 activation.
We have previously demonstrated that S1P is a potent activator
of IL-8 secretion in Beas-2B cells, with PLD involvement in the
signalling pathway [11]. In addition to regulation by PLD,
inhibitors of PKC and Rho kinase also attenuated IL-8 secretion
by S1P, indicating the involvement of multiple signalling path-
ways in the production and secretion of IL-8 [11]. Attempts to
use adenoviral constructs of PLD1 and PLD2 wild types in S1P-
induced IL-8 secretion were difficult, as the adenoviral vector
controls (LacZ) increased the basal secretion of IL-8 compared
with uninfected control cells. However, transient overexpression
of PLD1 and PLD2 wild-type plasmids with FuGENE 6 showed
increased IL-8 secretion compared with vector controls, con-
firming the participation of PLD1 and PLD2 in S1P-induced IL-
8 secretion.
Agonist-induced IL-8 secretion in epithelial and other cells is
regulated at the transcriptional level by the transcription factors
activator protein-1 (AP-1) and nuclear factor-κB (NF-κB). AP-
1 and NF-κB regulate IL-8 gene transcription both individually
and synergistically [48]. MAPK activation increases both AP-1
expression and activity [49]. Our results provide evidence that
PLD activity regulates S1P-induced IL-8 secretion via, at least in
part, ERK1}2 activation. Regulation of NF-κB activation is very
complex, involving phosphorylation and dissociation of the
inhibitory protein IκBvia IκBkinase 1}2 and}or phosphorylation
of the RelA (p65) component of NK-κB by PKCζ and p21 Ras
[50]. PKCζ is not activated by Ca#+ or diacylglycerol ; however,
it is activated by several acidic phospholipids, including
phosphatidylinositol 3,4,5-trisphosphate and PA [51]. Therefore
it is possible that PA generated by the PLD pathway activates
NF-κB via PKCζ in Beas-2B cells. In human pulmonary en-
dothelial cells, hyperoxia-induced NF-κB activation was partially
blocked by butan-1-ol, but not butan-3-ol, suggesting a possible
role for PA in NF-κB activation (V. Natarajan, N. L. Parinandi,
M. A. Kleinberg, R. Cummings, L. Wang and P. Usatyuk,
unpublished work).
S1P-induced IL-8 secretion via PLD}PA and ERK signalling
is of physiological relevance in inflammatory diseases of the lung
and airway, such as asthma. IL-8 is a potent chemoattract-
ant and activator of neutrophils at sites of acute inflammation
[52], and elevated levels of IL-8 have been reported in the
bronchoalveolar lavage of patients with chronic lung diseases,
asthma, pulmonary sarcoidosis and the acute respiratory distress
syndrome [9,53,54]. Recent studies show elevated levels of S1P in
the airways of asthmatics, but not control subjects, following
segmental antigen challenge in association with smooth muscle
cell proliferation and IL-6 secretion [55]. Thus S1P-induced PLD
activation may function as a pro-inflammatory signal in airway
epithelial and other cells, regulating the secretion of chemotactic
factors and cytokines.
In summary, our results demonstrate that both PLD1 and
PLD2 are activated by S1P in airway epithelial cells. Fur-
thermore, PA generated by the PLD signal transduction pathway
regulates IL-8 secretion via Raf-dependent ERK phosphoryl-
ation. Further studies identifying downstream targets of PA-
dependent kinases, including PKCζ regulation of NF-κB ac-
tivation, are in progress.
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